Remember meForgot password?
    Log in with Twitter
Press Release

Sep 14, 2017 10:16 UTC

Global Angina Pectoris Drugs Market 2017-2021: Key Players are AstraZeneca, Gilead, Novartis & Pfizer - Research and Markets

DUBLIN--(Business Wire)--The "Global Angina Pectoris Drugs Market 2017-2021" report has been added to Research and Markets' offering.

The global angina pectoris drugs market is forecast to grow at a CAGR of 4.05% during the period 2017-2021.

The report, Global Angina Pectoris Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is launch of novel pharmacologic agents. There has been a continuous unmet demand for therapeutics in the angina pectoris drugs market. This, in turns, paves the way for entry of novel therapeutic agents in the market. Along with traditional therapeutic agents, trimetazidine, ivabradine, fasudil, and ranolazine represent a promising new therapeutic approach for the treatment of angina pectoris. Ranolazine, an antianginal agent, has been the first agent from any new drug class to be approved by the FDA for the treatment of angina pectoris.

According to the report, one driver in the market is increase in chronic diseases. Chronic diseases such as diabetes, high blood pressure, and obesity are some of the potential factors leading to angina pectoris. There has been a continuous rise in cases of these chronic diseases and some of them, such as diabetes, have turned into an epidemic, leading to huge concern from healthcare professionals across the globe. Diabetes increases the risk of developing number of serious health issues. Constant high blood glucose can lead to severe health conditions and affects eyes, heart and blood vessels, nerves, teeth, and kidneys.

Key vendors

  • AstraZeneca
  • Gilead
  • Novartis
  • Pfizer

Other prominent vendors

  • ABayer HealthCare
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Merck
  • Mylan
  • Teva Pharmaceutical

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market Landscape

Part 06: Pipeline Landscape

Part 07: Market Segmentation By Drug Class

Part 08: Geographical Segmentation

Part 09: Decision Framework

Part 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Key Vendor Analysis

Part 14: Appendix

For more information about this report visit

Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs